Background. Extensively drug resistant tuberculosis (XDR-TB) has been reported in 58 countries around the world and has emerged as a major public health challenge. Our objective was to determine the impact of pulmonary resection on XDR-TB treatment outcomes in a resourceconstrained setting.
with confirmed XDR-TB who underwent pulmonary resection. Data were collected on patient demographics, drug susceptibility profiles, and treatment regimens. Laboratory assessments included complete blood count, blood urea and electrolytes, albumin, and erythrocyte sedimentation rate. Preoperative diagnostic tests involved spirometry, plain chest radiography, highresolution computed axial tomography (HRCT) scans, and, if indicated, ventilation-perfusion isotope scans.
The indications for surgery consisted of failure of a treatment regimen appropriate for XDR-TB, complications of TB sequelae such as hemoptysis or recurrent chest infections, localized disease, and adequate pulmonary reserve to tolerate resection. Open pulmonary resection was performed using established techniques as previously described [16] . Excised specimens were submitted for histology examination and microbiology culture. After surgery, the drug treatment regimen was continued for approximately 18 months, and patients were reviewed on a monthly outpatient basis at the TB clinic at KGV Hospital, a referral center that specializes in medical management of drug-resistant tuberculosis.
Treatment outcomes of cure, default, failure, and death, were designated according to the standard multidrug resistant tuberculosis (MDR-TB) definitions [17] . Default status was defined as an interruption in treatment lasting at least 2 months in duration. Patients who demonstrated culture positivity in at least two of the five cultures in the final 12 months, culture positivity in any of the final three cultures, or based on clinical or radiographic features, were designated as treatment failures. Death was classified as resulting from any cause while on treatment. Treatment cure was considered a favorable outcome, whereas treatment failure, default, and death were considered unfavorable. This study was approved by the Biomedical Ethics Review Committee at the University of KwaZulu-Natal.
Results
Of the 11 XDR-TB patients referred for pulmonary resection, 6 demonstrated bilateral, extensive, cavitatory disease, and therefore did not meet the criteria for surgical intervention. Demographic features of the 5 surgical patients are presented in Table 1 .
All patients demonstrated resistance to at least six drugs, and their baseline drug susceptibility profiles of the patients are presented in Table 2 . Preoperative chemotherapy regimens, radiographic features, the extent of pulmonary resection undertaken, and treatment outcomes are presented in Tables 3 and 4 . All patients were on an individualized chemotherapy regimen consisting of at least five drugs (median, six drugs) based on their respective drug susceptibility results. Drugs to which resistance was noted were used in regimens when no other drugs were available. Postoperative chemotherapy was continued for at least 7 months, and all patients undergoing surgery demonstrated unilateral disease. Operative procedures included pneumonectomies and upper lobectomies. There was no operative mortality, and all patients achieved culture conversion by the conclusion of the study period. 
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Comment
In this study, we describe excellent clinical and microbiologic outcomes using adjuvant pulmonary resection for XDR-TB management. All of the patients successfully achieved sputum conversion and obtained favorable treatment outcomes. This cohort did not experience any complications other than a pneumothorax, which was not directly related to the surgery. The use of pulmonary resection for XDR-TB has been previously described, but has been reported to be complicated by bronchopulmonary fistulas, empyema, postpneumonectomy syndrome, and less favorable treatment outcomes [12] . The selection of suitable surgical candidates warrants further discussion. Ideally, the patient should be nutritionally sound (as assessed by standard anthropometric tests, body mass index, and serum albumin) and in [19] , thereby providing an opportunity for the use of pulmonary resection in tuberculosis management. Figures 1 and 2 illustrate examples of the radiographic manifestations of the XDR-TB patients involved in this study. Although these features are not pathognomonic of drug-resistant TB, they demonstrate evidence of sequelar TB (bronchiectasis and cavitation) and active parenchymal TB ("tree-inbud" nodules). The aggressive surgical attitude should thus be tempered by an individualized, pragmatic approach incorporating nutritional status, pulmonary reserve, HRCT features, and anticipated pleural space problems in association with insufficient residual lung volume.
The principles for lung resection outlined by Naidoo and Reddi [16] for MDR-TB and inflammatory lung disease were applied to the resection in the 5 patients with XDR-TB in this study. In our view, the role of video-assisted thorascopic surgery is extremely limited for a variety of reasons in this cohort, and thoracotomy is our preference. An adherence to the simple principles of anastomotic technique, namely, a tension-free suture line, maintenance of adequate tissue blood supply, and membranous flap closure for pneumonectomy, made bronchial stump closure with absorbable interrupted sutures without a muscle pedicle feasible in all our cases.
Although the timing of surgery in XDR-TB management has not been established, Iseman and coworkers [20] recommended at least 3 months of preoperative chemotherapy. In our study, the duration on preoperative chemotherapy ranged from 2.3 to 10.8 months. The findings from our study support early surgical intervention in appropriately selected patients followed by postoperative chemotherapy to promote healing of the bronchial stump and remove residual parenchymal disease, which may be present preoperatively or as a result of contralateral contamination or "spill." A conservative approach to surgical intervention in patients with active tuberculosis is unnecessary, and, paradoxically, persistent sputum positivity remains a strong indication for surgery to appropriately selected candidates with drug resistant TB [21] . This is the first report of its kind from Africa, which has the highest incidence of TB in the world. According to WHO data, approximately 69,000 cases of drug-resistant TB emerged in Africa 2008, with rates in some southern African countries at least five times higher than those of India and China [1] . South Africa is one of the high TB burden countries, and nearly 72% of TB patients are coinfected with HIV. Indeed, the original cohort of XDR-TB patients from Tugela Ferry were coinfected with HIV and demonstrated mortality approaching 100% [3] . Subsequent reports have confirmed the high early mor- According to WHO data, female TB patients in South Africa are 1.2 times more likely to exhibit drug resistant strains of M tuberculosis [24] . In addition, 2 of the female patients in this study were health care workers, both of whom had a previous history of pulmonary TB before being diagnosed with XDR-TB. Similar to recent reports of drug-resistant tuberculosis in South African health care workers [25, 26] , XDR-TB in the health care workers of this study did not appear to be associated with HIV infection. Considering their sex and occupation (nurses are more likely to be female), nosocomial acquisition of XDR-TB is likely [27] . However, without molecular epidemiologic methods, it was not possible to determine the transmission dynamics of the infections. As health care workers are continuously exposed to patients, in addition to their families and communities, it is imperative that hospitals improve infection control measures through policies that reduce the spread of tuberculosis, especially drug-resistant strains of M tuberculosis.
Several limitations of our study warrant further discussion. First, as a retrospective chart review, the results are dependent upon previously recorded information, which may be influenced by incomplete data and recorder bias. Second, patients were required to meet stringent criteria before surgery could be performed, resulting in the small number of patients in this single-arm study. Furthermore, as XDR-TB was defined in 2006, prior resections may have been undertaken in patients with XDR-TB that were simply labeled MDR-TB.
In conclusion, although XDR-TB has been associated with high mortality and treatment failure rates, our results show the potential for effective adjuvant surgical methods in a group of highly selected patients with XDR-TB. Despite the discussed limitations, we are confident that appropriate pharmacologic and surgical intervention, coupled with early diagnostics and proper infection control measures, can reduce the burden of the XDR-TB. Increased communication between pulmonary physicians and thoracic surgeons may also enhance the capacity of XDR-TB management, as early surgical intervention may be appropriate for patients with persistent sputum positivity. Future studies should focus on long-term assessment of the South African cohort that has undergone surgery. In addition, prospective studies comparing chemotherapy with combined pulmonary resection and chemotherapy would provide more conclusive evidence of the efficacy of surgery in managing XDR-TB.
